BOSTON, Mass., June 4 /PRNewswire-FirstCall/ -- Experts with in-depth product development and regulatory strategy experience from PAREXEL International Corporation , a leading global biopharmaceutical services organization, will attend the 2008 BIO International Convention to be held June 17-20, 2008 at the San Diego Convention Center in San Diego, California. PAREXEL has worked with the top 10 global biotechnology companies, and has helped hundreds of small and mid-size biopharmaceutical companies develop and implement product and regulatory strategies as well as maximize product value at every milestone and phase of development.
PAREXEL is a sponsor of the Business Forum, one of the largest partnering events in the world, which will be held during the BIO convention. The Business Forum offers opportunities for biotechnology and pharmaceutical companies, academic institutions, and investors to present, meet, and discuss business opportunities of mutual interest.
Biopharmaceutical companies attending the BIO convention can visit Booth 1337 to speak with PAREXEL experts about integrated solutions to help them reach critical clinical milestones and successfully develop products for regional and international markets. Attendees can learn about PAREXEL's expertise in product development, all phases of clinical research, enabling eClinical technologies, and medical communications. Additionally, companies can find out how to leverage PAREXEL's global platform, providing a wide array of geographies in which to conduct clinical development programs, and access local and global regulatory experience.
Hosted by the Biotechnology Industry Organization (BIO), the 2008 BIO International Convention will bring together more than 20,000 industry and business leaders, scientists, and investors from more than 60 countries. The convention will address the drivers behind new medicine, processes, and other areas of the global biotechnology industry.
For more information about PAREXEL visit www.PAREXEL.com or Booth 1337 at the BIO convention.
About PAREXEL International
PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 63 locations throughout 52 countries around the world, and has more than 7,600 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the period ended March 31, 2008 as filed with the SEC on May 9, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.
CONTACT: Jennifer Baird, Senior Director of Public Relations of PAREXEL
International, +1-781-434-4409, Jennifer.Baird@PAREXEL.com, or Rebecca
Passo of SHIFT Communications, +1-617-779-1817, rpasso@shiftcomm.com, for
PAREXEL International Corporation
Web site: http://www.parexel.com/
